Stryker Co. (NYSE:SYK) Shares Purchased by Voisard Asset Management Group Inc.

Voisard Asset Management Group Inc. lifted its holdings in Stryker Co. (NYSE:SYK) by 1,981.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 895 shares of the medical technology company’s stock after purchasing an additional 852 shares during the quarter. Voisard Asset Management Group Inc.’s holdings in Stryker were worth $323,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Koshinski Asset Management Inc. acquired a new stake in Stryker during the 1st quarter worth about $795,000. Envestnet Portfolio Solutions Inc. raised its stake in shares of Stryker by 43.1% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 18,491 shares of the medical technology company’s stock valued at $6,617,000 after buying an additional 5,565 shares during the last quarter. Norden Group LLC purchased a new position in shares of Stryker during the 1st quarter valued at about $4,027,000. BI Asset Management Fondsmaeglerselskab A S raised its stake in shares of Stryker by 38.5% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 19,796 shares of the medical technology company’s stock valued at $7,084,000 after buying an additional 5,502 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its stake in shares of Stryker by 78.9% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company’s stock valued at $45,260,000 after buying an additional 58,673 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In related news, insider Viju Menon sold 600 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares in the company, valued at approximately $3,219,495. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Stryker news, insider Viju Menon sold 600 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the transaction, the insider now owns 9,069 shares of the company’s stock, valued at $3,219,495. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Glenn S. Boehnlein sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the completion of the sale, the chief financial officer now directly owns 2,852 shares in the company, valued at $949,716. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 220,068 shares of company stock valued at $71,811,372. 5.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. JPMorgan Chase & Co. lifted their price objective on Stryker from $375.00 to $420.00 and gave the company an “overweight” rating in a research note on Wednesday. Truist Financial lifted their price target on Stryker from $370.00 to $380.00 and gave the company a “hold” rating in a research note on Wednesday. UBS Group boosted their price objective on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research report on Wednesday. BTIG Research increased their target price on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Canaccord Genuity Group boosted their price target on shares of Stryker from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Wednesday. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $392.60.

Stryker Stock Performance

Shares of Stryker stock opened at $363.48 on Thursday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.95 and a current ratio of 1.68. The business’s 50 day moving average price is $359.79 and its 200 day moving average price is $343.98. The company has a market cap of $138.47 billion, a price-to-earnings ratio of 41.49, a PEG ratio of 2.73 and a beta of 0.91. Stryker Co. has a one year low of $264.85 and a one year high of $374.63.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.78 by $0.09. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The firm had revenue of $5.49 billion for the quarter, compared to analysts’ expectations of $5.37 billion. During the same quarter in the previous year, the company posted $2.46 EPS. The company’s revenue was up 11.9% compared to the same quarter last year. On average, research analysts predict that Stryker Co. will post 12 EPS for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be issued a dividend of $0.80 per share. The ex-dividend date is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.88%. Stryker’s dividend payout ratio is currently 36.53%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.